Drug Pricing Policy, Diagnostics Advances Dominate

Pfizer ($PFE) closed at $24.48, up 1.28%, as investors weighed drug pricing developments and pipeline strength. The Trump administration's drug-pricing deals are reshaping the competitive landscape for $PFE, AbbVie, and Bristol Myers Squibb, with analysts noting that pipelines matter even more than pricing in determining long-term value. Abbott Laboratories ($ABT) is down 23% this year, while $PFE offers a 7% yield, with both beating Q1 estimates amid sector-wide pricing pressure. Eli Lilly ($LLY) passed Navellier's high-growth screen, demonstrating exceptional sales, earnings, and cash flow growth despite the evolving pricing environment.

Dexcom ($DXCM) announced Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System for people 18 years and older living with diabetes, extending wear time and continuity for Canadian adults. The global blood glucose monitoring system market was valued at approximately $16.8 billion in 2025 and is expected to reach $18.3 billion in 2026, growing to $39.4 billion by 2035 at a CAGR of 8.9%. Abbott ($ABT) is positioned in this expanding diagnostics market alongside $DXCM and Insulet Corporation. Alamar Biosciences shares climbed 7.3% to a new 52-week high of $28.42 on Alzheimer's diagnostics momentum, while the S&P 500 gained 0.4%.

UnitedHealth Group ($UNH) faces Q2 pressure from membership declines ahead of July 16 earnings, though medical cost management and long-term growth initiatives remain investor focus areas. Johnson & Johnson ($JNJ) hit fresh all-time highs last week, with Q2 results scheduled for Wednesday, July 15, before the opening bell. The company maintains its Dividend King status with more than 60 consecutive years of payout increases, and is advancing chronic kidney disease therapies alongside AstraZeneca, Novartis, Bayer, and Amgen.

Madrigal Pharmaceuticals announced it received three new U.S. patents for its lead drug Rezdiffra, sparking retail trader buzz over M&A speculation and intellectual property protection for its liver disease therapy. The head and neck squamous cell carcinoma market is projected to grow at a CAGR of 10.5% during the forecast period, driven by rising incidence of head and neck cancers worldwide and the expected launch of emerging therapies including Amivantamab from Johnson & Johnson ($JNJ), BNT113 from BioNTech, and other novel immunotherapies. Opportunities in chronic kidney disease care include integrating cardio-renal strategies, aligning therapies with real-world evidence, and leveraging site-of-care economics.

Johnson & Johnson ($JNJ) reports Q2 earnings Wednesday morning, with investors watching for guidance on the MedTech segment and pharmaceutical pipeline updates. UnitedHealth ($UNH) follows on July 16, with membership trends and medical cost ratios as key metrics. Analysts continue monitoring the impact of drug pricing negotiations on Big Pharma margins, particularly for companies facing patent cliffs alongside pricing pressure.